Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling

Abstract

The ubiquitin-proteasome pathway (UPP) is involved in regulating several biological functions, including cell cycle control, apoptosis, DNA damage response, and apoptosis. It is widely known for its role in degrading abnormal protein substrates and maintaining physiological body functions via ubiquitinating enzymes (E1, E2, E3) and the proteasome. Therefore, aberrant expression in these enzymes results in an altered biological process, including transduction signaling for cell death and survival, resulting in cancer. In this review, an overview of profuse enzymes involved as a pro-oncogenic or progressive growth factor in tumors with their downstream signaling pathways has been discussed. A systematic literature review of PubMed, Medline, Bentham, Scopus, and EMBASE (Elsevier) databases was carried out to understand the nature of the extensive work done on modulation of ubiquitin-proteasome pathways in oncogenic signaling. Various in vitro, in vivo studies demonstrating the involvement of ubiquitin-proteasome systems in varied types of cancers and the downstream signaling pathways involved are also discussed in the current review. Several inhibitors of E1, E2, E3, deubiquitinase enzymes and proteasome have been applied for treating cancer. Some of these drugs have exhibited successful outcomes in in vivo studies on different cancer types, so clinical trials are going on for these inhibitors. This review mainly focuses on certain ubiquitin-proteasome enzymes involved in developing cancers and certain enzymes that can be targeted to treat cancer.

Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination

“…The virus has an affinity to bind with the ACE2 receptor, which is found in both the lungs and the heart. A cytokine release storm develops when T cell activation is imbalanced, resulting in the inappropriate release of cytokines such as IL-17, IL-6, and others, potentially causing substantial cellular damage (Sharma et al 2021a , b). Moreover, this strong immune response may cause plaque instability, leading to acute coronary syndrome (ACS) development (Long et al 2020 ).…”

“…In addition, due to COVID-19, PD’s non-motor and motor symptoms will aggravate significantly (Bloem et al 2021 ). It is very well known that the typical non-motor characteristics of PD are ageusia and anosmia (Sharma et al 2021a , b ). Therefore, during COVID-19, the episode of hypogeusia and hyposmia could be a slight “hit” for the potential development of PD symptoms (Boika 2020 ).…”

The Multifaceted Role of Curcumin in Advanced Nanocurcumin Form in the Treatment and Management of Chronic Disorders

“…Excessive inflammatory activation for long periods of time can result in mitochondrial dysfunction. Traumatic brain injuries (TBI), spinal cord injuries (SCI), and hemorrhagic/ischemic stroke all cause substantial changes in mitochondrial dynamics, notably increased membrane permeabilization, oxidative phosphorylation, and the accumulation of mitochondrial ROS [ 31 , 32 ]. Excessive glial activation has been linked to the same outcomes as long-term inflammation.…”

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?

“…Then, a trans-thioesterification reaction allows the transfer of a molecule of Ub from E1 to E2. Lastly, an E3 binds at the same time the E2-Ub conjugate and the target protein favouring the transfer of Ub from the E2 to the substrate, directly or indirectly depending on the E3 family involved in the event ( Infante et al, 2019 ; Sharma et al, 2021 ). Both the number of Ub moieties and the lysine linkage of Ub-Ub conjugation determine the fate of the protein ( Welchman et al, 2005 ).…”